Transmedics Group Inc
NASDAQ:TMDX

Watchlist Manager
Transmedics Group Inc Logo
Transmedics Group Inc
NASDAQ:TMDX
Watchlist
Price: 136.51 USD -1.53% Market Closed
Market Cap: 4.7B USD

Transmedics Group Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Transmedics Group Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Transmedics Group Inc
NASDAQ:TMDX
Operating Income
$95.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Operating Income
$3.8B
CAGR 3-Years
24%
CAGR 5-Years
29%
CAGR 10-Years
15%
Stryker Corp
NYSE:SYK
Operating Income
$5.4B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Operating Income
$8B
CAGR 3-Years
-6%
CAGR 5-Years
13%
CAGR 10-Years
11%
IDEXX Laboratories Inc
NASDAQ:IDXX
Operating Income
$1.3B
CAGR 3-Years
14%
CAGR 5-Years
16%
CAGR 10-Years
17%
Intuitive Surgical Inc
NASDAQ:ISRG
Operating Income
$2.8B
CAGR 3-Years
19%
CAGR 5-Years
22%
CAGR 10-Years
15%
No Stocks Found

Transmedics Group Inc
Glance View

TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists. Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.

TMDX Intrinsic Value
HIDDEN
Show

See Also

What is Transmedics Group Inc's Operating Income?
Operating Income
95.6m USD

Based on the financial report for Sep 30, 2025, Transmedics Group Inc's Operating Income amounts to 95.6m USD.

What is Transmedics Group Inc's Operating Income growth rate?
Operating Income CAGR 1Y
204%

Over the last year, the Operating Income growth was 204%.

Back to Top